Qtorin rapamycin PDUFA date: FDA decision expected February 28, 2027
The FDA is expected to decide on Qtorin rapamycin from Ligand Pharmaceuticals Incorporated in microcystic lymphatic malformations by the PDUFA target action date of February 28, 2027. For microcystic lymphatic malformations. NDA filing. Extracted from SEC filing: EX-99.1
A PDUFA date is the FDA's target deadline to complete its review of a drug application — approval, a complete response letter (CRL), or an extension are all possible. What is a PDUFA date? This page is research information, not financial advice.
Source: sec.gov · Data checked October 29, 2026. How we check dates. Confirm dates against the company's or the FDA's announcement before acting.
Get an email when this FDA date moves or the decision lands
Track Ligand Pharmaceuticals Incorporated (LGND) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Questions about this FDA decision
- When is the PDUFA date for Qtorin rapamycin?
- The FDA's PDUFA target action date for Qtorin rapamycin is February 28, 2027. The FDA can act before that date, and the review can be extended.
- What is Qtorin rapamycin being reviewed for?
- The application under FDA review covers microcystic lymphatic malformations.
- Which company is developing Qtorin rapamycin?
- Ligand Pharmaceuticals Incorporated (LGND).
- What can happen on a PDUFA date?
- The FDA approves the application, issues a complete response letter (CRL) listing what must be fixed before approval, or extends the review (typically by three months after a major amendment).